Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9U4FO)

• Drug Name: Benzonatate Drug Info
• Synonyms: Benzonatato; Benzonatatum; Benzononantin; Benzononatine; Exangit; Tesalon; Tessalin; Tessalon; Ventussin; Tessalon Perles; KM65; Benzonatato [INN-Spanish]; Benzonatatum [INN-Latin]; Tessalon Capsules (TN); Tessalon Perles (TN); Tessalon perles (TN); Tessalon-ciba; Ventussin-loz; Benzonatate (USP/INN); Benzonatate [USAN:INN:BAN];Nonaethyleneglycol monomethyl ether p-n-butylaminobenzoate; P-butylaminobenzoic acid omega-O-methylnonaethyleneglycol ester; Polyethyleneglycol-p-n-butylaminobenzoate methyl ester; P-(n)-Butylaminobenzoesaeure-(nonaaethylenglykol-monomethylaether)-ester; P-(n)-Butylaminobenzoesaeure-(nonaaethylenglykol-monomethylaether)-ester [German]; Benzoic acid, 4-(butylamino)-, 2,5,8,11,14,17,20,23,26-nonaoxaoctacos-28-yl ester; Benzoic acid, 4-(butylamino)-, 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl ester; Benzoic acid, 4-(butylamino)-, 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl ester (9CI); Benzoic acid, p-(butylamino)-, 2-(2-(2-(2-(2-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl ester; 2,5,8,11,14,17,20,23,26-Nonaoxaoctacosan-28-yl p-(butylamino)benzoate; 2,5,8,11,14,17,20,23,26-nonaoxaoctacosan-28-yl 4-(butylamino)benzoate; 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-(butylamino)benzoate; 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-butylaminobenzoate; 3,6,9,12,15,18,21,24,27-Nonaoxaoctacos-1-yl 4-(butylamino)benzoate; 3,6,9,12,15,18,21,24,27-nonaoxaoctacosyl 4-butylaminobenzoate; 4-(butylamino)benzoic acid 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl ester

Indication

Disease Entry	ICD 11	Status	REF
Cough	MD12	Approved	[1]

• Therapeutic Class: Antitussives
• Cross-matching ID:
  PubChem CID: 7699
  ChEBI ID: CHEBI:3032
  CAS Number: CAS 104-31-4
  TTD Drug ID: DM9U4FO
  ACDINA Drug ID: D00062

Molecule-Related Drug Atlas

Drug(s) Targeting Voltage-gated sodium channel alpha Nav1.5 (SCN5A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Mephenytoin	DM5UGDK	Epilepsy	8A60-8A68	Approved	[3]
Mexiletine	DMCTE9R	Ventricular tachycardia	BC71	Approved	[4]
Fosphenytoin	DMOX3LB	Epilepsy	8A60-8A68	Approved	[3]
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[4]
LOMERIZINE	DME0TC8	Migraine	8A80	Approved	[5]
Tetrodotoxin	DMWMPRG	Bacterial infection	1A00-1C4Z	Approved	[6]
Dyclonine	DMU6OFP	Pain	MG30-MG3Z	Approved	[7]
Moricizine	DMOMBJW	Arrhythmia	BC9Z	Approved	[8]
Ethotoin	DMXWOCP	Complex partial seizure	8A68.0	Approved	[2]
Prilocaine	DMI7DZ2	Pain	MG30-MG3Z	Approved	[7]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated sodium channel alpha Nav1.5 (SCN5A)	TTZOVE0	SCN5A_HUMAN	Blocker	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7611).
• [2] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [3] Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68.
• [4] Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9.
• [5] Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
• [6] Halothane attenuates the cerebroprotective action of several Na+ and Ca2+ channel blockers via reversal of their ion channel blockade. Eur J Pharmacol. 2002 Oct 4;452(2):175-81.
• [7] Monoamine transporter and sodium channel mechanisms in the rapid pressor response to cocaine. Pharmacol Biochem Behav. 1998 Feb;59(2):305-12.
• [8] From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials. Am J Cardiol. 1996 Aug 29;78(4A):28-33.